AbbVie (NYSE:ABBV) Price Target Raised to $285.00

AbbVie (NYSE:ABBV) had its price objective raised by Cantor Fitzgerald from $265.00 to $285.00 in a research note published on Monday,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Canaccord Genuity Group increased their price objective on shares of AbbVie from $273.00 to $282.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Guggenheim raised their price objective on shares of AbbVie from $249.00 to $261.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Morgan Stanley upped their price target on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Evercore set a $235.00 price objective on shares of AbbVie in a report on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $272.76.

AbbVie Stock Up 0.9%

Shares of NYSE:ABBV opened at $245.98 on Monday. The firm has a market cap of $434.59 billion, a P/E ratio of 69.49, a P/E/G ratio of 0.81 and a beta of 0.30. AbbVie has a 12-month low of $190.75 and a 12-month high of $267.47. The business has a fifty day simple moving average of $240.90 and a 200 day simple moving average of $224.61.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts expect that AbbVie will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at approximately $28,000. Imprint Wealth LLC lifted its holdings in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in AbbVie during the 4th quarter worth about $31,000. Legacy Wealth Managment LLC ID boosted its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares during the period. Finally, WestEnd Advisors LLC grew its holdings in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after buying an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund an acquisition. While the financing increases interest obligations, it provides capital to pursue a transaction intended to strengthen the company’s growth profile. AbbVie prices $9.9B senior notes to fund acquisition
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group upgraded AbbVie from “hold” to “buy,” while Cantor Fitzgerald raised its price target to $285, implying additional upside from recent trading levels. Cantor Fitzgerald boosts AbbVie price target
• Positive Sentiment: Second-quarter results exceeded expectations: revenue increased 10.2% year over year to $16.99 billion, and adjusted EPS of $3.65 surpassed the $3.61 consensus estimate. Growth in immunology and neuroscience helped offset concerns about the post-Humira transition, while third-quarter EPS guidance of $3.84–$3.88 indicates continued earnings momentum. AbbVie Q2 results and outlook
• Positive Sentiment: The FDA accepted Allergan Aesthetics’ supplemental application for BOTOX Cosmetic in masseter muscle prominence, expanding a major product into a potential new aesthetic indication. Approval could broaden BOTOX’s revenue opportunity, although the application still requires regulatory review. FDA accepts BOTOX Cosmetic application
• Positive Sentiment: Canada’s drug agency recommended conditional reimbursement of UBRELVY for acute migraine treatment, potentially improving access and supporting international growth for the newer migraine medicine. UBRELVY reimbursement recommendation
• Neutral Sentiment: RemeGen forecast a significant profit turnaround, citing stronger drug sales and an AbbVie licensing deal. The development supports AbbVie’s partnered pipeline but is unlikely to materially affect near-term results. RemeGen licensing update
• Negative Sentiment: Valuation remains a risk. Commentary noted ABBV’s trailing P/E near 70 and a model estimating fair value roughly $50 below the current level, raising concerns that much of the positive outlook may already be reflected in the stock. AbbVie year-end price prediction

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.